XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Data
 9 Months Ended
Sep. 28, 2018
Segment Reporting [Abstract]  
Segment Data
19.
Segment Data
The Company's continuing operations are limited to the results of operations from the Specialty Brands segment as the Specialty Generics Disposal Group is reported as a discontinued operation. See Note 4 for further details on the Specialty Generics Disposal Group. Selected information for the reportable segment is as follows:

Three Months Ended
 
Nine Months Ended

September 28,
2018
 
September 29,
2017
 
September 28,
2018
 
September 29,
2017
Net sales:
 
 
 
 
 
 
 
Specialty Brands
$
640.0

 
$
600.6

 
$
1,844.3

 
$
1,760.7

Operating income:
 
 
 
 
 
 
 
Specialty Brands
$
287.8

 
$
314.8

 
$
794.0

 
$
851.8

Unallocated amounts:
 
 
 
 
 
 
 
Corporate and unallocated expenses (1)          
(28.0
)
 
(45.8
)
 
(81.9
)
 
(95.0
)
Intangible asset amortization
(184.2
)
 
(169.3
)
 
(544.8
)
 
(508.4
)
Restructuring and related charges, net (2)
(19.6
)
 
(16.1
)
 
(101.4
)
 
(28.4
)
Operating income
$
56.0

 
$
83.6

 
$
65.9

 
$
220.0


(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
(2)
Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's reportable segment is as follows:
 
Three Months Ended
 
Nine Months Ended
 
September 28,
2018
 
September 29,
2017
 
September 28,
2018
 
September 29,
2017
H.P. Acthar Gel
$
290.1

 
$
308.7

 
$
827.1

 
$
899.9

Inomax
133.2

 
125.7

 
404.0

 
379.6

Ofirmev
87.1

 
75.4

 
254.7

 
224.5

Therakos
60.0

 
55.3

 
174.2

 
157.7

Amitiza (1)
48.2

 
—

 
119.2

 
—

BioVectra
13.9

 
16.0

 
35.7

 
36.4

Other
7.5

 
19.5

 
29.4

 
62.6

Net sales
$
640.0

 
$
600.6

 
$
1,844.3

 
$
1,760.7


(1) Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.